Fig. 5.

Effects of bortezomib growth and NF-κΒ activity of established lung adenocarcinoma. (A) Experimental setup of tumor growth studies in C57BL/6 mice. Red arrows indicate LLC implantation; horizontal gray arrow indicates period of bortezomib treatment; black arrows indicate mouse termination time points. Mice received either wild-type or NF-κΒ reporter LLC cells. (B) Tumor volume (n = 5 per group). (C) Representative microphotographs of immunoreactivity of flank tumors for PCNA (left panels) and respective isotype controls (right panels) at 4 weeks (Å = 400; scale bar = 100 μm) (D) Tumor-restricted NF-κB activity (n = 5 per group). (E) Representative bioluminescence images at 3 and 21 days post-LLC transplant with pseudocolor scale bar; colored areas emit light stemming exclusively from tumor cells. Circles, mean; bars, SD. ***P < 0.001 compared with saline-treated mice.